Research Topics
Species | Jürgen Kurt RockstrohSummaryAffiliation: University of Bonn Country: Germany Publications
| Collaborators
|
Detail Information
Publications
How important is HIV therapy for preventing liver fibrosis progression in HIV-HCV-coinfected individuals?Jürgen Kurt Rockstroh
Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany
Antivir Ther 17:1223-5. 2012....
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive IndividualsM Vogel
Department of Internal Medicine I, Rheinische Friedrich Wilhelms University, Germany
Eur J Med Res 15:102-11. 2010..In addition a control group of HCV mono-infected patients undergoing anti-HCV therapy was evaluated...- Hepatic profile analyses of tipranavir in Phase II and III clinical trialsJaromir Mikl
SUNY at Albany, School of Public Health, Rensselaer NY, USA
BMC Infect Dis 9:203. 2009.... - Integrase inhibitors: why do we need a new drug class for HIV therapy?Jurgen K Rockstroh
Bonn University, Department of Medicine I, Sigmund Freud Str 25, 53105 Bonn, Germany
Eur J Med Res 14:1-3. 2009..Clearly more data is needed to further explore and define the future role of integrase inhibitors in HIV-care... - The treatment of chronic hepatitis C virus infection in HIV co-infectionMartin Vogel
Department of Internal Medicine I, Bonn University, Bonn, Germany
Eur J Med Res 14:507-15. 2009..However, these substances will probably reach clinical routine for HIV patients later than HCV monoinfected patients. Therefore at present waiting for new drugs is not an alternative to a modern pegylated interferon/ribavirin therapy... - Hot topics in HIV and hepatitis coinfection: noninvasive diagnosis of liver disease, liver transplantation, and new drugs for treatment of hepatitis coinfectionJürgen Kurt Rockstroh
Department of Medicine, University of Bonn, Bonn, Germany
HIV Clin Trials 10:110-5. 2009.... - [Rational use of modern substances for the treatment of HIV-infection]J K Rockstroh
Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Bonn, Deutschland
Internist (Berl) 49:1463-4, 1466-9. 2008..The significance of new drugs in the clinical setting will be defined more precisely in the near future, as all new substances have been licensed for pre-treated patients only so far... 
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapyJurgen K Rockstroh
Department of Medicine I, University Hospital Bonn, Bonn, Germany
J Infect Dis 192:992-1002. 2005....- European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adultsJ K Rockstroh
Department of Medicine I, University of Bonn, Bonn, Germany
HIV Med 9:82-8. 2008..With the introduction of new agents for the treatment of hepatitis B and increased knowledge of how best to manage hepatitis C, an update of current guidelines for management of HBV and HCV coinfection with HIV is warranted... - Adherence to enfuvirtide and its impact on treatment efficacyJurgen Rockstroh
Medizinische Klinik I, University of Bonn, Bonn, Germany
AIDS Res Hum Retroviruses 24:141-8. 2008..825). Adherence was high in patients receiving the self-injectable ARV enfuvirtide. In addition, the inclusion of ENF did not negatively impact adherence to the ARV regimen as a whole... - Is there a need for liver disease monitoring in HIV patients in Africa?Jurgen K Rockstroh
Department of Medicine I, University of Bonn, Germany
Antivir Ther 16:287-9. 2011..These results were independent from hepatitis status, initiating a discussion on the need for future liver disease monitoring in these particular patient groups... - Should HIV/HCV coinfected patients with severe hepatitis be treated for hepatitis CJ K Rockstroh
Medizinische Universitatsklinik I, Bonn
Presse Med 34:1585-8. 2005..IMPACT OF HAART: Antiretroviral treatment seems to have a positive effect on the course of hepatitis C that exceeds its risk of hepatotoxicity... - Management of late-presenting patients with HIV infectionJurgen K Rockstroh
Department of Medicine I, University of Bonn, Bonn, Germany
Antivir Ther 15:25-30. 2010..The choice of initial HIV treatment should reflect patient characteristics, the results of resistance testing and the complexity of concomitant disease... - Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapyM Lichterfeld
Department of General Internal Medicine, University of Bonn, Berlin, Germany
HIV Med 3:37-43. 2002.... - Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven casesM Vogel
Medizinische Klinik und Poliklinik I, Bonn University, Germany
J Viral Hepat 12:207-11. 2005..In conclusion, early treatment of acute hepatitis C seems to achieve high sustained virological treatment response rates also in patients with HIV-infection... - First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week resultsE Voigt
Department of Internal Medicine I, University of Bonn, Germany
HIV Med 3:277-82. 2002..However, discontinuation due to adverse events, especially nephrotoxicity, is frequent and limits treatment duration. Therefore, extra hydration appears inevitable with this combination... - Influence of viral hepatitis on HIV infectionJürgen Kurt Rockstroh
Department of Medicine I, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
J Hepatol 44:S25-7. 2006..There is, however, an increased risk of liver disease related morbidity and mortality as well as more hepatoxicity under antiretroviral treatment regimens... - T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditionsM Altfeld
Department of Internal Medicine I, University of Bonn, Germany
J Acquir Immune Defic Syndr 23:287-94. 2000..Therefore, we determined tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-4, IL-10, and interferon-gamma (IFN-gamma) mRNA and serum levels in HIV-infected patients under nonstimulated conditions... - [HIV-infection]J-C Wasmuth
Medizinische Klinik und Poliklinik I, Bonn
Dtsch Med Wochenschr 132:673-83; quiz 685-6. 2007 - Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapyJ K Rockstroh
Department of Medicine, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
Eur J Med Res 4:271-4. 1999..Our data suggest that HIV-infected patients resistant to indinavir or ritonavir and double NRTI combination therapy respond to double PI nelfinavir/saquinavir and D4T rescue therapy only initially but have no sustained benefit... - Antiretroviral drug toxicity -- a challenge for the hepatologist?Ulrich Spengler
Department of General Internal Medicine I, Universitatsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
J Hepatol 36:283-94. 2002 - Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapyM Lichterfeld
Department of General Internal Medicine, , Bonn, Germany
Eur J Med Res 8:56-60. 2003..5% and 56.7% (p = 0.09) in the respective study cohorts. Ritonavir-boosted protease inhibitors therefore seem to induce a superior virological response rate and a higher degree of sustained virological suppression... - [Chronic HIV infection. Current therapeutic aspects]M Vogel
Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Sigmund Freud Str 25, 53127 Bonn
Internist (Berl) 48:519-24; quiz 525. 2007..Each patient should be counseled according to present treatment guidelines on when and how to start HAART, taking into account the surrogate markers CD4-cell count and HIV-RNA as well as clinically apparent HIV-associated disease... - [HIV and hepatitis C co-infection]M Vogel
Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn
Dtsch Med Wochenschr 135:1186-91. 2010..In this review we summarize the current epidemiology, natural course of HCV in HIV co-infection and current guidelines for management of chronic hepatitis C infection in HIV co-infected patients... - Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapyM P Look
Department of Internal Medicine I, University of Bonn, Bonn, Germany
Metabolism 50:1275-81. 2001.... - Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patientsJürgen Kurt Rockstroh
Department of Medicine I, University of Bonn, Germany
AIDS 16:2083-5. 2002..In HIV/HCV-co-infected patients, the therapeutic benefit of high-dose IFN-alpha therefore seems to be limited by its poor tolerability... - Diagnosis and treatment of acute hepatitis C virus infectionChristoph Boesecke
Department of Internal Medicine I, Bonn University Hospital, Sigmund Freud Strase 25, 53105 Bonn, Germany
Infect Dis Clin North Am 26:995-1010. 2012..This article addresses similarities and differences in the epidemiology, diagnosis, and management of AHC monoinfection and coinfection... - HIV and hepatitis C virus co-infectionJürgen Kurt Rockstroh
HIV Outpatient Clinic, and Department of Medicine I, University of Bonn, Bonn, Germany
Lancet Infect Dis 4:437-44. 2004..Owing to the high rates of HIV and HCV co-infection worldwide, new improved treatment strategies and guidelines for the management of co-infection remain a major future goal... - Drug safety evaluation of maraviroc for the treatment of HIV infectionJan Christian Wasmuth
Universitatsklinikum Bonn, Medical Department I, Sigmund Freud Str 25, 53105 Bonn, Germany
Expert Opin Drug Saf 11:161-74. 2012..EXPERT OPINION: Maraviroc is a generally safe and well-tolerated medication for the treatment of HIV-1 infection with a unique mechanism of action. Long-term (i.e., > 5 years) risks are not known and have to be carefully monitored... - Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challengesJohannes Carl Christoph Lenz
University of Bonn, Medicine I, Sigmund Freudstr 25, Bonn 53105, Germany
Expert Opin Drug Metab Toxicol 6:1139-50. 2010..CCR5 inhibitors are believed to possibly decrease inflammation from the immune system and thereby offer additional properties further to their antiretroviral efficacy... - Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicityJ C Wasmuth
Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105, Bonn, Germany
Eur J Clin Pharmacol 63:901-8. 2007..We tested whether dose reduction of IDV guided by therapeutic drug monitoring resulted in improved tolerability without compromising antiviral efficacy... - Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoringJ C Wasmuth
Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
Eur J Med Res 12:289-94. 2007..To compare two reduced dose indinavir (IDV) + ritonavir (RTV) combinations guided by therapeutic drug monitoring (TDM) in treatment-naive HIV1-infected patients... - Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetenceM Vogel
Department of Internal Medicine I, Bonn University, Sigmund Freud Str 25, 53105 Bonn, Germany
Eur J Med Res 16:101-7. 2011..To estimate the cancer risk of HIV-infected patients in the HAART era with respect to a general reference population and to determine risk factors for malignancy... - [Orthotopic liver transplantation in a 33-year-old patient with fulminant hepatitis B and HIV infection]K Schliefer
Medizinische Klinik und Poliklinik I, Universitat Bonn
Dtsch Med Wochenschr 125:523-6. 2000..A 33-year-old man with fulminant hepatitis B infection was to have an orthotopic liver transplantation (OLTX) because of the otherwise poor prognosis. During preparations for it he was found also to have an HIV-infection... - Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?E Anadol
Department of General Internal Medicine, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
Eur J Med Res 15:225-30. 2010..Alternatively, this effect could be explained with a different antiviral potency for the respective PIs used... - [HIV and hepatitis coinfection]P Ingiliz
, Bonn
Dtsch Med Wochenschr 130:S216-8. 2005 - [Therapy of hepatitis B and hepatitis C coinfection in HIV patients]M Vogel
Medizinische Universitatsklinik I, Bonn
MMW Fortschr Med 147:56-9. 2005..Thus, HAART should not be withheld from a patient because of hepatitis coinfection. When cirrhosis is present, semiannual prophylactic checkups are recommended to monitor the occurrence of hepatocellular carcinoma... - New aspects in the treatment of AIDS-related lymphomaI G H Schmidt-Wolf
Medizinische Universitätsklinik und Poliklinik I, Rheinische Friedrich Wilhelms Universitat, Bonn, Germany
Eur J Med Res 7:295-303. 2002..It is hoped that novel strategies will lead to a survival benefit in these patients. In this review, we discuss the current strategies for the treatment of AIDS-related lymphoma... - [Progressive multifocal leukoencephalopathy]J C Wasmuth
Universitätsklinik Bonn
Med Klin (Munich) 94:264-73. 1999..TREATMENT: A specific therapy is not yet available or established. Highly active antiretroviral therapy (HAART) and cidofovir are promising and may prove useful in the near future... - Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patientsR P Woitas
Department of Internal Medicine I, University of Bonn, Germany
AIDS 13:1313-22. 1999..Epidemiological data indicate that hepatitis C virus (HCV) infection runs a more rapid and severe course of disease in HIV-coinfected patients, probably because of an altered immune response... - [Hepatitis C and HIV coinfection. Current aspects of therapy]J K Rockstroh
Universitätsklinik und Poliklinik I, Universitatsklinikum Bonn
MMW Fortschr Med 144:30-2. 2002.... - Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective studyH Palmedo
Department of Nuclear Medicine, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
Radiology 221:256-60. 2001..In six (75%) of eight patients, a single injection of (186)Re HEDP led to an improvement in disease activity. Systemic low-dose treatment with (186)Re HEDP can reduce pain and disease activity in patients with polyarthritis... - Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 diseaseM P Look
Department of General Internal Medicine, University of Bonn, Germany
AIDS Res Hum Retroviruses 16:1215-21. 2000..This eventually led to a decrease in quinolinic acid formation. The parallel reduction of the immune activation marker sTNFR p75 supports this hypothesis... - Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standardsF L Dumoulin
Department of Medicine I, University of Bonn, Germany
J Immunol Methods 241:109-19. 2000..The method was successfully applied to the semi-quantification of chemokines in human liver specimens and should be useful in further studies on steady state mRNA levels of C-C chemokines from low cell numbers or small tissue specimens... - Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosisJ C Wasmuth
Department of General Internal Medicine, University of Bonn, Germany
J Acquir Immune Defic Syndr 23:44-51. 2000..The aim of the study was to compare accepted surrogate markers of HIV disease progression with markers of lymphocyte apoptosis in their ability to predict short-term disease progression... - [Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?]R P Woitas
Medizinische Klinik und Poliklinik I, Hugstetter, Freiburg, Germany
Dtsch Med Wochenschr 127:1807-12. 2002..While the CCR5-Delta32 mutation is also increased in chronic hepatitis C virus (HCV) infection it is unclear, whether the CCR2b-V64 I and the SDF-1 3'A polymorphisms also are associated with chronic HCV infection... - Enteric dysfunction in patients with asymptomatic HIV-infection versus patients with hypoproteinemia/hypalbuminemia and advanced HIV-infectionJ C Wasmuth
Department of Internal Medicine I, University of Bonn, Germany
Eur J Med Res 7:536-42. 2002..It is unclear whether enteric dysfunction and protein losses contribute to hypoproteinemia, which heralds poor survival in HIV infection... - Malignant thymoma: current status of classification and multimodality treatmentI G H Schmidt-Wolf
Medizinische Klinik und Poliklinik I, Rheinische Friedrich Wilhelms Universitat, Sigmund Freud Str 25, 53105 Bonn, Germany
Ann Hematol 82:69-76. 2003..In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma... - Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot studyM P Look
Department of General Internal Medicine, University of Bonn, Germany
Eur J Clin Invest 28:389-97. 1998.... - Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapyJ C Wasmuth
Department of Internal Medicine I, University of Bonn, Germany
HIV Med 4:111-9. 2003..To assess the effect of highly active antiretroviral therapy (HAART) on surrogate markers of lymphocyte apoptosis in HIV 1-infected individuals... - [HIV-infection: modern antiretroviral therapy]J K Rockstroh
,
Dtsch Med Wochenschr 129:1921-4. 2004 - Therapy of hepatitis C in HIV-coinfectionJ K Rockstroh
Medizinische Universitatsklinik I, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
Eur J Med Res 9:304-8. 2004.... - Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week resultsE Voigt
Department of Internal Medicine, University of Bonn, Sigmund Freud Str 25, D 53105, Bonn, Germany
Infection 32:82-8. 2004..Within this open-label, uncontrolled prospective trial we evaluated safety, efficacy and development of genotypic resistance under the new protease inhibitor lopinavir/ritonavir (LPV/r) in antiretroviral (ARV) HIV patients... - Clinical perspective of fusion inhibitors for treatment of HIVJ K Rockstroh
Department of Medicine I, University of Bonn, Bonn, Germany
J Antimicrob Chemother 53:700-2. 2004..In this article, the characteristics and clinical perspectives of fusion inhibitors are presented and discussed... - Semiquantitation of human chemokine mRNA levels with a newly constructed multispecific competitor fragmentF L Dumoulin
Department of General Internal Medicine, University of Bonn, Germany
J Immunol Methods 224:61-7. 1999..The assay should be useful for further studies, in particular for the semiquantitation of chemokine mRNA species from small cell or tissue specimens... - Influence of protease inhibitor therapy on lipoprotein metabolismH K Berthold
Department of Internal Medicine I, University of Bonn, Germany
J Intern Med 246:567-75. 1999.... - Acute hepatitis C in patients with HIVChristoph Boesecke
Department of Internal Medicine I, University of Bonn, Bonn, Germany
Semin Liver Dis 32:130-7. 2012..Prevention and screening efforts along with early anti-HCV therapy have to be intensified to allow for control of viral dissemination as the current epidemic of AHC particularly among MSM is still ongoing... - The treatment of patients with HIVMartin Vogel
Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn
Dtsch Arztebl Int 107:507-15; quiz 516. 2010..Infection with the human immunodeficiency virus (HIV) remains a major medical challenge... - S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challengesJohannes Carl Christoph Lenz
University of Bonn, Medicine I, Bonn, Germany
Expert Opin Investig Drugs 20:537-48. 2011..EXPERT OPINION: S/GSK1349572 represents a new, unboosted, once-daily INI in development with distinct pharmacokinetics and resistance profile, which has showed promising potency and tolerability in the first clinical studies... - Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiationP Ingiliz
Department of Medicine I, University of Bonn, Bonn, Germany
HIV Med 7:411-4. 2006..He improved dramatically after treatment with oral steroids... - Management of hepatitis B and C in HIV co-infected patientsJürgen Kurt Rockstroh
University of Bonn, Bonn, Germany
J Acquir Immune Defic Syndr 34:S59-65. 2003..The high number of HIV/HCV and HIV/HBV co-infections, as well as the much more unfavorable course of HBV and HCV in these patients, underlines the need to establish treatment strategies for HBV and HCV in HIV co-infected individuals... - Determination of nevirapine in plasma by GC-MSM Vogel
Department of Internal Medicine I, Bonn University, Bonn, Germany
J Chromatogr Sci 48:91-4. 2010..GC-MS proved to be a valid alternative to high-performance liquid chromatography and liquid chromatography-MS... - CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literatureJ M Emmelkamp
Department of Medicine I, University Clinic Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
Eur J Med Res 12:409-17. 2007..Extended follow-up of the vicriviroc trials showed no further case of malignancy, reassuring the overall good tolerability profile of the drug so far... - Elevated serum activity of N-acetyl-beta-glucosaminidase in essential hypertension: diagnostic value and reversal to normal values after antihypertensive therapyR E Schmieder
Department of Medicine, University of Bonn, Bonn Venusberg, Germany
Am J Kidney Dis 18:638-48. 1991..We conclude that in patients with mild essential hypertension, serum NAG activity was already elevated (whereas urinary NAG activity was not) and was normalized by effective antihypertensive treatment.(ABSTRACT TRUNCATED AT 400 WORDS)..